Clinical trial · Interventional
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer
NCT04158700CI-TRIAL-00043506withdrawnPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.
Summary
Brief summary (as posted)
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY3200882 | Drug | — | UNRESOLVED |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- LY3200882 and Pembrolizumab (Dose Level 1)
- description
- Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered intravenously (IV).
- interventionNames
- Drug: LY3200882
- Drug: Pembrolizumab
- type
- EXPERIMENTAL
- label
- LY3200882 and Pembrolizumab (Dose Level 2)
- description
- Participants with urothelial carcinoma: LY3200882 administered orally with pembrolizumab administered IV.
- interventionNames
- Drug: LY3200882
- Drug: Pembrolizumab
- type
- EXPERIMENTAL
- label
- LY3200882 and Pembrolizumab Expansion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study \[for example, nivolumab, pembrolizumab, atezolizumab\] * Participants must be willing to have tumor biopsies * Participants must have adequate organ function * Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 * Participants must be able to swallow tablets * Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days Exclusion Criteria: * Participants must not have moderate or severe cardiovascular disease * Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc) * Participants must not have an active infection requiring treatment
References
Publications (0)
Data not yet available
No reference posted for this study.